‘pH Pharma’s Global Strategy’. The reason why licensing-in of German and Belgian new drug candidates

Hoyoung Huh, CEO, who has experience in IPO, M&A in global biotech, founded pH Pharma in 2015..licensing-in of new drug candidates from around the world, development within short-term and technology transfer strategy..phase 2b for glaucoma treatment completed and phase 1b for Non-alcoholic steatohepatitis treatment progressed(For more information, please refer to...

1Q Venture Fund to Bioand Medical Soaring and Hallyu Losing

In the first quarter of this year, venture funds were found to be concentrated in biomedical and medical treatment. On the other hand, investment in Hallyu content, which increased every year until last year, was reported to be decreasing.(For more information, please refer to the link below)http://news.mk.co.kr/newsRead.php?&year=2017&no=281527